Drug Profile
Research programme: GABA-A receptor positive allosteric modulators - BioCrea
Alternative Names: LT GABA-A PAMs - BioCreaLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator biocrea GmbH
- Class Small molecules
- Mechanism of Action GABA A receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Autistic disorder; Epilepsy
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for research development in Autistic-disorder in Germany
- 28 Jul 2018 No recent reports of development identified for research development in Epilepsy in Germany
- 23 Apr 2014 BioCrea is actively seeking to out-license or partner its GABA-A receptor positive allosteric modulators programme as of 23 Apr 2014. http://www.biocrea.com